Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2
Proceedings of the National Academy of Sciences · 07.03.2023 · 120 (10)
DOI: 10.1073/pnas.2214561120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 28.02.2023. Verfasst von Jordana Muñoz-Basagoiti und 30 weiteren Autor:innen. Beteiligte Einrichtung: IrsiCaixa Acquired Immune Deficiency Syndrome Research Institute, Badalona 08916, Spain. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CCR NIH HHS, NCI NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped positive stranded RNA virus which has caused the recent deadly pandemic called COVID-19. The SARS-CoV-2 virion is coated with a heavily glycosylated Spike glycoprotein which is responsible for attachment and entry into target cells. One, as yet unexploited strategy for preventing SARS-CoV-2 infections, is the targeting of the glycans on Spike. Lectins are carbohydrate-binding proteins produced by plants, algae, and cyanobacteria. Some lectins can neutralize enveloped viruses displaying external glycoproteins, offering an alternative therapeutic approach for the prevention of infection with virulent β-coronaviruses, such as SARS-CoV-2. Here we show that the cyanobacterial lectin cyanovirin-N (CV-N) can selectively target SARS-CoV-2 Spike oligosaccharides and inhibit SARS-CoV-2 infection in vitro and in vivo. CV-N neutralizes Delta and Omicron variants in vitro better than earlier circulating viral variants. CV-N binds selectively to Spike with a Kd as low as 15 nM and a stoichiometry of 2 CV-N: 1 Spike but does not bind to the receptor binding domain (RBD). Further mapping of CV-N binding sites on Spike shows that select high-mannose oligosaccharides in the S1 domain of Spike are targeted by CV-N. CV-N also reduced viral loads in the nares and lungs in vivo to protect hamsters against a lethal viral challenge. In summary, we present an anti-coronavirus agent that works by an unexploited mechanism and prevents infection by a broad range of SARS-CoV-2 strains.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IrsiCaixa Acquired Immune Deficiency Syndrome Research Institute, Badalona 08916, Spain.
- Laboratory of Molecular Virology, Institute of Biology, Department of Genetics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-90, Brazil.
- Molecular Targets Program, Center for Cancer Research, National Cancer Institute-Frederick, NIH, Frederick, MD 21702.
- Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702.
- Department of Crop and Forest Sciences, University of Lleida-Agrotecnio Center, Lleida 25198, Spain.
- Laboratory of Diversity and Viral Diseases, Institute of Genetics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-90, Brazil.
ORCID-Profile: Jordana Muñoz-Basagoiti, Fábio Luís Lima Monteiro, Lauren R H Krumpe, Victoria Armario-Najera, Gemma Villorbina, Curtis J Henrich, Pascual Torres, Jennifer Wilson, Mirela D'arc, Silvia Marfil, Alice Laschuk Herlinger, Edwards Pradenas, Manuel Portero-Otin, Richard M Twyman, Julià Blanco, Nuria Izquierdo-Useros, Elibio L Rech
Förderung
- CCR NIH HHS
- NCI NIH HHS
- Intramural NIH HHS
- Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España
- Spanish Ministry of Science and Innovation
- Embrapa Genetic Resources and Biotechnology/National Institute of Science and Technology in Synthetic Biology, National Council for Scientific and Technologica…
- Research Support Foundation of the Federal District
- Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research
Zitieren
APA
Muñoz-Basagoiti, J., Monteiro, F. L. L., Krumpe, L. R. H., Armario-Najera, V., Shenoy, S. R., Perez-Zsolt, D., Westgarth, H. J., Villorbina, G., Bomfim, L. M., Raïch-Regué, D., Nogueras, L., Henrich, C. J., Gallemí, M., Moreira, F. R. R., Torres, P., Wilson, J., D'arc, M., Marfil, S., Herlinger, A. L., …, & O'Keefe, B. R. (2023). Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2. Proceedings of the National Academy of Sciences, 120(10). https://doi.org/10.1073/pnas.2214561120
Vancouver
Muñoz-Basagoiti J, Monteiro FLL, Krumpe LRH, Armario-Najera V, Shenoy SR, Perez-Zsolt D, et al. Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2. Proceedings of the National Academy of Sciences. 2023;120(10). doi:10.1073/pnas.2214561120
BibTeX
@article{MuozBasagoiti2023,
author = {Muñoz-Basagoiti, Jordana and Monteiro, Fábio Luís Lima and Krumpe, Lauren R H and Armario-Najera, Victoria and Shenoy, Shilpa R and Perez-Zsolt, Daniel and Westgarth, Harrison James and Villorbina, Gemma and Bomfim, Larissa Maciel and Raïch-Regué, Dàlia and Nogueras, Lara and Henrich, Curtis J and Gallemí, Marçal and Moreira, Filipe Romero Rebello and Torres, Pascual and Wilson, Jennifer and D'arc, Mirela and Marfil, Silvia and Herlinger, Alice Laschuk and Pradenas, Edwards and Higa, Luiza Mendonça and Portero-Otin, Manuel and Trinité, Benjamin and Twyman, Richard M and Capell, Teresa and Tanuri, Amilcar and Blanco, Julià and Izquierdo-Useros, Nuria and Rech, Elibio L and Christou, Paul and O'Keefe, Barry R},
title = {Cyanovirin-N binds to select SARS-CoV-2 spike oligosaccharides outside of the receptor binding domain and blocks infection by SARS-CoV-2},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
volume = {120},
number = {10},
doi = {10.1073/pnas.2214561120}
}
EUVIMED